[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking University People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,181,0,25,[9,46,70,96,126,148,176,199,224,250,267,286,312,342,369,394,418,436,453,478,502,525,544,567,579],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053974",false,"NCT07366112","CDK4\u002F6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment","CDK4\u002F6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment of Breast Cancer: ctDNA-Guided Personalized Therapy","DNACDKHR","Inclusion Criteria:\n\n* 1.Female breast cancer patients aged ≥18 years and ≤75 years, either postmenopausal or premenopausal\u002Fperimenopausal; 2.Pathologically confirmed hormone receptor-positive (HR+), HER2-negative invasive breast cancer:\n\n  1. ER-positive and\u002For PR-positive defined as: ≥10% of tumor cells showing positive staining;\n  2. HER2-negative defined as: standard immunohistochemistry (IHC) result of 0\u002F1+; or IHC 2+ with negative in situ hybridization (ISH) (confirmed by the central pathology laboratory); 3. At least one evaluable lesion per RECIST 1.1, with clinical staging meeting:\n\n  \u003C!-- -->\n\n  1. T1c-2N0M0 with high-risk factors (Grade 3, or Grade 2 with Ki67 ≥20%);\n  2. T3N0M0;\n  3. Any TN+M0; 4.Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; 5.Willing to participate in the study and voluntarily sign informed consent; 6.Agree to undergo ctDNA testing during treatment; 7.Adequate organ and bone marrow function defined as:\n\n  \u003C!-- -->\n\n  1. Absolute neutrophil count (ANC) ≥1,500\u002Fmm³ (1.5 × 10⁹\u002FL) (without granulocyte colony-stimulating factor \\[G-CSF\\] treatment within 14 days);\n  2. Platelet count (PLT) ≥100,000\u002Fmm³ (100 × 10⁹\u002FL) (without corrective therapy within 7 days);\n  3. Hemoglobin (Hb) ≥9 g\u002FdL (90 g\u002FL) (without corrective therapy within 7 days);\n  4. Serum creatinine ≤1.5× upper limit of normal (ULN) or creatinine clearance ≥60 mL\u002Fmin (without corrective therapy within 7 days);\n  5. Total bilirubin (TBIL) ≤1.5×ULN (without corrective therapy within 7 days);\n  6. Aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤1.5×ULN (without corrective therapy within 7 days);\n  7. Cardiac function: left ventricular ejection fraction (LVEF) ≥55%; QTc interval corrected by Fridericia's formula (QTcF) \\\u003C470 msec on 12-lead ECG; Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization and agree to use non-hormonal contraception from informed consent signing until 2 months after the last treatment.\n\nExclusion Criteria:\n\n* 1.Bilateral breast cancer; 2.Prior history of breast cancer (including ductal carcinoma in situ or invasive breast cancer); 3.Any prior antitumor therapy for the current breast cancer, including systemic therapies (endocrine, chemotherapy, immunotherapy, biological therapy) or local therapies (radiotherapy, vascular embolization, axillary lymph node biopsy); 4.Diagnosis of any malignancy within 5 years prior to randomization, except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin; 5.History of severe pulmonary diseases (e.g., interstitial pneumonia); 6. HIV infection, acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥500 IU\u002FmL), hepatitis C (HCV antibody-positive with HCV RNA above the lower limit of detection), or co-infection with HBV and HCV; 7.Within 6 months prior to randomization: myocardial infarction, severe\u002Funstable angina, NYHA Class ≥II heart failure, ≥Grade 2 persistent arrhythmia (per NCI CTCAE v5.0), atrial fibrillation of any grade, coronary\u002Fperipheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack), or symptomatic pulmonary embolism; 8.Severe active infection within 4 weeks prior to randomization (requiring intravenous antibiotics, antifungals, or antivirals) or unexplained fever \\>38.5°C during screening\u002Fbefore first dose; 9.Known allergy to any component of the study drugs; 10.Current participation in another interventional drug clinical study; 11.Pregnancy or lactation; 12.Refusal to comply with follow-up; 13.Other severe physical\u002Fmental illnesses or laboratory abnormalities that may increase study risk, interfere with results, or render the patient unsuitable per investigator judgment.","FEMALE","18 Years","75 Years",{"count":21,"type":22},158,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4\u002F6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy",[28,29,30,31,32],"Hormone Receptor-Positive Breast Cancer","High-risk Breast Cancer","Early-Stage Breast Cancer","HER2-negative Breast Cancer","ctDNA Monitoring","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-04-20",{"date":41,"type":22},"2029-12-31",{"name":43,"class":44},"Peking University People's Hospital","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100053386","NCT07238894","A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients","Peking University People's Hospital Breast Surgery Department","Inclusion Criteria:\n\n* 1\\) Aged 18 or above; 2) Breast cancer confirmed by core needle biopsy; 3) Tumor lesions clearly visible on ultrasound; 4) No contraindications for cryoablation such as coagulation disorders; 5) Presence of reasons unsuitable for conventional surgical resection: patient's condition cannot tolerate general anesthesia or surgical treatment; due to unresectable and\u002For metastatic disease; patient refuses surgery, etc.; 6) Agree to undergo ablation surgery and sign the consent form.\n\nExclusion Criteria:\n\n* 1\\) Missing clinical and pathological data (such as imaging and pathological materials); 2) Pregnant or lactating women; 3) Known allergies, intolerances, or contraindications to cryotherapy (such as cryoglobulinemia, presence of implanted electronic devices); 4) Vulnerable populations, including those with neurological disorders, cognitive impairments, critically ill patients, etc.",true,"80 Years",{"count":55,"type":22},200,[57],"NA","Although surgical resection is the gold standard for early breast cancer treatment, some patients cannot tolerate surgery due to medical conditions or refuse surgical treatment for cosmetic reasons. In recent years, the rapid development of ablation technology has provided new directions for breast cancer patients who are not suitable for surgical treatment. Ablation uses high or low temperatures to deactivate lesions or tissues, which are gradually absorbed by the body, achieving local treatment purposes. Its safety and efficacy have been preliminarily confirmed. As an advanced minimally invasive medical device independently developed in China, the combined cryo-thermal ablation system treats tumors using a combined mode of deep cryogenic freezing and high-intensity heating. It has been approved for ablation treatment of various solid tumors including lung cancer, pancreatic cancer, kidney cancer, prostate cancer, breast cancer, bone and soft tissue sarcomas.\n\nThis project proposes a prospective cohort design, based on the breast disease cohort database of Peking University People's Hospital Breast Center. It will enroll patients pathologically diagnosed with breast cancer, determined unsuitable for surgical treatment, and have received combined cryo-thermal ablation. The registered data will be used to evaluate the effectiveness and safety of percutaneous ultrasound-guided cryo-thermal composite ablation in this population.",[60,61],"Ablation","Breast Cancer",[63],"Combined Cryoablation and Thermal Ablation",{"date":36,"type":37},{"date":66,"type":37},"2026-03-03",{"date":68,"type":22},"2028-10-01",{"name":43,"class":44},{"id":71,"slug":4,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100053594","NCT07600164","Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer","Real-world Study of Pyrotinib-containing Regimens in First-line or Second-line Treatment of Advanced HER2-positive Breast Cancer","Inclusion Criteria:\n\n1. Aged ≥ 18 years old;\n2. Histopathologically confirmed HER2-positive inoperable locally advanced or metastatic breast cancer;\n3. Patients with first-line or second-line advanced disease:\n\n   First-line advanced disease: no prior systemic therapy for locally advanced or metastatic disease. For patients who received neoadjuvant or adjuvant therapy, the disease-free interval (DFI) after the completion of the last chemotherapy or HER2-targeted therapy was more than 12 months; Second-line advanced disease: prior treatment with taxane combined with trastuzumab, with or without pertuzumab, in the advanced setting; or recurrence occurring during neoadjuvant\u002Fadjuvant therapy, or a disease-free interval (DFI) of ≤ 12 months after completion of the last neoadjuvant\u002Fadjuvant chemotherapy and HER2-targeted therapy;\n4. Planned to receive pyrotinib-containing regimen, and judged by investigators based on clinical practice to have potential subsequent treatment with Ruikang trastuzumab after failure of pyrotinib-containing therapy;\n5. Traceable medical records available throughout the treatment period.\n\nExclusion Criteria:\n\n1. Failure to sign the informed consent form;\n2. Pregnant or lactating females;\n3. Patients participating in any interventional clinical trial involving investigational drugs or marketed drugs at enrollment;\n4. Other conditions deemed ineligible for enrollment by the investigator's judgment.","ALL",{"count":78,"type":22},500,[80],"PHASE4","Given that pyrotinib has been proven to exert significant efficacy against HER2-positive advanced breast cancer in multiple Phase III studies, and the novel ADC drug disitamab vedotin has demonstrated potent anti-tumor activity, there remains insufficient real-world data on their sequential administration. This multicenter, prospective real-world study plans to enroll 500 patients with HER2-positive advanced breast cancer receiving first-line or second-line treatment. It aims to evaluate the efficacy and safety of sequential disitamab vedotin treatment after disease progression or intolerance to pyrotinib-based regimens (first-line: pyrotinib plus trastuzumab combined with chemotherapy; second-line: pyrotinib plus capecitabine). The primary endpoint is real-world second progression-free survival (rwPFS2), while secondary endpoints cover real-world progression-free survival (rwPFS), tumor response, overall survival (OS), time to treatment failure, safety profiles and patient-reported outcomes. It is currently expected to further validate the efficacy and safety of pyrotinib in patients with advanced HER2-positive breast cancer in the real-world setting, and to evaluate the efficacy and safety of recindopril trastuzumab following pyrotinib-containing regimens.",[83,84],"HER2 + Breast Cancer","Advanced Breast Cancer",[86,87,88,89],"HER2-positive breast cancer","Advanced breast cancer","pyrotinib","Trastuzumab Rezetecan",{"date":36,"type":37},{"date":92,"type":37},"2026-07-06",{"date":94,"type":22},"2031-12-30",{"name":43,"class":44},{"id":97,"slug":4,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":45},"100053782","NCT06970912","ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive\u002FHER2-Negative Breast Cancer","A Prospective, Multicenter, Randomized, Open-Label Phase II Study of ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive\u002FHER2-Negative Breast Cancer","DNADalHR","Inclusion Criteria:\n\n* Female breast cancer patients aged ≥18 years and ≤75 years, either postmenopausal or premenopausal\u002Fperimenopausal;\n* Pathologically confirmed hormone receptor-positive (HR+), HER2-negative invasive breast cancer:\n\n  1. ER-positive and\u002For PR-positive defined as: ≥10% of tumor cells showing positive staining;\n  2. HER2-negative defined as: standard immunohistochemistry (IHC) result of 0\u002F1+; or IHC 2+ with negative in situ hybridization (ISH) (confirmed by the central pathology laboratory);\n* At least one evaluable lesion per RECIST 1.1, with clinical staging meeting:\n\n  1. T1c-2N0M0 with high-risk factors (Grade 3, or Grade 2 with Ki67 ≥20%);\n  2. T3N0M0;\n  3. Any TN+M0;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n* Willing to participate in the study and voluntarily sign informed consent;\n* Agree to undergo ctDNA testing during treatment;\n* Adequate organ and bone marrow function defined as:\n\n  1. Absolute neutrophil count (ANC) ≥1,500\u002Fmm³ (1.5 × 10⁹\u002FL) (without granulocyte colony-stimulating factor \\[G-CSF\\] treatment within 14 days);\n  2. Platelet count (PLT) ≥100,000\u002Fmm³ (100 × 10⁹\u002FL) (without corrective therapy within 7 days);\n  3. Hemoglobin (Hb) ≥9 g\u002FdL (90 g\u002FL) (without corrective therapy within 7 days);\n  4. Serum creatinine ≤1.5× upper limit of normal (ULN) or creatinine clearance ≥60 mL\u002Fmin (without corrective therapy within 7 days);\n  5. Total bilirubin (TBIL) ≤1.5×ULN (without corrective therapy within 7 days);\n  6. Aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤1.5×ULN (without corrective therapy within 7 days);\n  7. Cardiac function: left ventricular ejection fraction (LVEF) ≥55%; QTc interval corrected by Fridericia's formula (QTcF) \\\u003C470 msec on 12-lead ECG;\n* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization and agree to use non-hormonal contraception from informed consent signing until 2 months after the last treatment.\n\nExclusion Criteria:\n\n* HER2-positive breast cancer confirmed by current pathological diagnosis;\n* Inflammatory breast cancer;\n* Stage IV (metastatic) breast cancer;\n* Bilateral breast cancer;\n* Prior history of breast cancer (including ductal carcinoma in situ or invasive breast cancer);\n* Any prior antitumor therapy for the current breast cancer, including systemic therapies (endocrine, chemotherapy, immunotherapy, biological therapy) or local therapies (radiotherapy, vascular embolization, axillary lymph node biopsy);\n* Diagnosis of any malignancy within 5 years prior to randomization, except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin;\n* History of severe pulmonary diseases (e.g., interstitial pneumonia);\n* HIV infection, acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥500 IU\u002FmL), hepatitis C (HCV antibody-positive with HCV RNA above the lower limit of detection), or co-infection with HBV and HCV;\n* Within 6 months prior to randomization: myocardial infarction, severe\u002Funstable angina, NYHA Class ≥II heart failure, ≥Grade 2 persistent arrhythmia (per NCI CTCAE v5.0), atrial fibrillation of any grade, coronary\u002Fperipheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack), or symptomatic pulmonary embolism;\n* Severe active infection within 4 weeks prior to randomization (requiring intravenous antibiotics, antifungals, or antivirals) or unexplained fever \\>38.5°C during screening\u002Fbefore first dose;\n* Known allergy to any component of the study drugs;\n* Current participation in another interventional drug clinical study;\n* Pregnancy or lactation;\n* Refusal to comply with follow-up;\n* Other severe physical\u002Fmental illnesses or laboratory abnormalities that may increase study risk, interfere with results, or render the patient unsuitable per investigator judgment.",{"count":104,"type":22},393,[25],"* This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer. The study aims to determine if combining the CDK4\u002F6 inhibitor Dalpiciclib with endocrine therapy can reduce the need for chemotherapy while maintaining clinical benefits.\n* Key Details ：\n\n  1. Participants: 393 women (aged 18-75) with early-stage HR+\u002FHER2- breast cancer at high risk of recurrence (e.g., tumor size ≥2 cm, lymph node involvement, or high-grade tumors).\n  2. Design: Patients are randomized 1:4 to two groups:\n\n     Group A (Chemotherapy) : Receives 4 cycles of taxane-based chemotherapy before surgery.\n\n     Group B (Experimental) : Receives Dalpiciclib + aromatase inhibitor (AI) for 4 cycles pre-surgery.\n\n     Post-surgery, treatment is adjusted based on ctDNA results.\n  3. Primary Goals ： Assess ctDNA clearance rate (conversion from detectable to undetectable ctDNA) after neoadjuvant therapy in Group B.\n\n     Evaluate 3-year event-free survival (EFS) in Group B (e.g., freedom from cancer recurrence, progression, or death).\n\n     Secondary Goals ： Safety of Dalpiciclib + endocrine therapy. Tumor response rates (e.g., complete cell cycle arrest, pathological remission).\n\n     Correlation between ctDNA clearance and long-term outcomes.\n* Why This Matters ： Current guidelines recommend chemotherapy for high-risk HR+ breast cancer, but it often causes significant side effects. This study explores a personalized approach using ctDNA-a blood-based biomarker-to identify patients who may safely avoid chemotherapy without compromising survival. If successful, it could shift clinical practice toward less toxic, targeted therapies for eligible patients.",[28,29,30,31,32,108],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[110,111,112,113,114,115,116,117,118,119,120],"HR-positive HER2-negative breast cancer","Early-stage breast cancer","Dalpiciclib","CDK4\u002F6 inhibitor","ctDNA-guided therapy","Adjuvant chemotherapy de-escalation","Circulating tumor DNA (ctDNA)","Event-free survival (EFS)","Chemotherapy sparing","Personalized therapy","Biomarker-guided therapy",{"date":36,"type":37},{"date":123,"type":37},"2025-08-01",{"date":41,"type":22},{"name":43,"class":44},{"id":127,"slug":4,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":45},"100644986","NCT07677306","Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT","Prospective Cohort Study of Age-Stratified Busulfan-Based Conditioning Regimens in Adult Patients With Myelodysplastic Syndrome Receiving Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients who had low- and intermediate-risk MDS without ISD nor URD receiving haploidentical hematopoietic stem cell transplantation\n\nExclusion Criteria:\n\n* Patients having ISD or URD; patients having high-risk MDS; patients with active infection; patients with poor compliance; patients with organ failure","65 Years",{"count":134,"type":22},120,[25],"This study plan aims to enroll adult patients diagnosed with myelodysplastic syndrome (MDS) who are scheduled to receive T-cell-replete haploidentical hematopoietic stem cell transplantation. After obtaining written informed consent, participants will receive either reduced-toxicity Bu\u002FFlu\u002FCy\u002FATG conditioning regimen (for patients aged ≥55 years) or standard myeloablative modified Bu\u002FCy+ATG conditioning regimen (for patients aged \\\u003C55 years) followed by unified post-transplant immunosuppression and supportive care. The objective is to prospectively characterize the 1-year transplant-related mortality and comprehensively evaluate hematopoietic engraftment, graft-versus-host disease, infection, relapse, survival outcomes and conditioning-related organ toxicity among all enrolled patients undergoing haploidentical transplantation.",[138],"Myelodysplastic Syndromes","NOT_YET_RECRUITING","2026-06-24",{"date":142,"type":37},"2026-06-30",{"date":144,"type":22},"2026-07-15",{"date":146,"type":22},"2028-06-30",{"name":43,"class":44},{"id":149,"slug":4,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":19,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":45},"100641248","NCT07656766","Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer","A Single-Arm, Open-Label, Exploratory Phase II Clinical Trial of Sintilimab Plus Gossypol Acetate in Patients With Advanced pMMR\u002FMSS Colorectal Cancer After Failure of at Least Two Prior Lines of Therapy","Inclusion Criteria:\n\n1. Written informed consent provided before any study-specific procedures.\n2. Age 18 to 75 years, male or female.\n3. Histologically or cytologically confirmed advanced colorectal adenocarcinoma.\n4. Confirmed pMMR\u002FMSS tumor status. Participants without documented MSI\u002FMMR status must undergo MSI or MMR testing during screening.\n5. Disease progression after at least two prior lines of standard therapy.\n6. Availability of tumor tissue suitable for pathological evaluation and biomarker analysis.\n7. ECOG performance status of 0 or 1 within 7 days before the first dose of study treatment.\n8. At least one measurable lesion according to RECIST version 1.1.\n9. Adequate hematologic, hepatic, renal, coagulation, and organ function as defined in the protocol.\n10. Female participants of childbearing potential must have a negative pregnancy test before initiation of study treatment and agree to use effective contraception during the study and for the protocol-specified period after the last dose.\n\nExclusion Criteria:\n\n1. Histology of small cell carcinoma, squamous cell carcinoma, or mixed carcinoma.\n2. dMMR\u002FMSI-H tumor status.\n3. Complete bowel obstruction or clinical conditions likely to progress to bowel obstruction.\n4. Suspected bowel perforation based on clinical symptoms or imaging.\n5. History of malignancy other than colorectal cancer within 3 years before screening, except malignancies with negligible risk of metastasis or death and treated with expected curative outcome.\n6. Active autoimmune disease, history of autoimmune disease, or immunodeficiency requiring systemic treatment, except protocol-allowed conditions.\n7. Significant cardiovascular disease within 3 months before initiation of study treatment, including New York Heart Association class II or higher heart disease, myocardial infarction, cerebrovascular accident, unstable arrhythmia, or unstable angina.\n8. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT.\n9. Severe chronic or active infection within 4 weeks before initiation of study treatment.\n10. Active tuberculosis infection or inadequately treated prior active tuberculosis.\n11. Active hepatitis B or hepatitis C infection as defined by protocol criteria.\n12. Uncontrolled tumor-related pain, uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.\n13. History of leptomeningeal disease.\n14. Prior treatment with CD137 agonists, T-cell co-stimulatory agents, or immune checkpoint inhibitors, including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-TIGIT antibodies.\n15. Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives before initiation of study treatment, whichever is longer.\n16. Treatment with systemic immunosuppressive medications within 2 weeks before initiation of study treatment, except protocol-allowed medications.\n17. Prior allogeneic stem cell transplantation or solid organ transplantation.\n18. Receipt of a live attenuated vaccine within 4 weeks before initiation of study treatment or expected need for such vaccination during the study or within 5 months after the last dose of sintilimab.\n19. Major surgery or severe traumatic injury within 28 days before initiation of study treatment, abdominal surgery or abdominal intervention within 60 days before initiation of study treatment, or expected need for major surgery during the study.\n20. Receipt of any other investigational drug within 28 days before initiation of study treatment.\n21. Known contraindication, hypersensitivity, or severe allergic reaction to any study drug or its excipients.\n22. Pregnancy, breastfeeding, or intention to become pregnant during the study or within 5 months after the last dose of sintilimab.\n23. Any other disease, laboratory abnormality, social condition, or medical condition that, in the investigator's judgment, may compromise participant safety, interfere with study compliance, or affect interpretation of study results.",{"count":155,"type":22},32,[25],"This is a single-center, open-label, single-arm, exploratory phase II clinical trial designed to evaluate the preliminary efficacy and safety of sintilimab in combination with oral gossypol acetate in patients with advanced pMMR\u002FMSS colorectal cancer after failure of at least two prior lines of standard therapy. Eligible participants will have histologically or cytologically confirmed advanced colorectal adenocarcinoma, measurable disease according to RECIST version 1.1, ECOG performance status of 0 or 1, and adequate organ function. Participants will receive oral gossypol acetate once daily, followed by sintilimab administered intravenously every 3 weeks after a gossypol acetate lead-in period. The primary outcome is objective response rate assessed by RECIST version 1.1. Secondary outcomes include disease control rate, progression-free survival, overall survival, duration of response, and safety.",[159],"Advanced Colorectal Cancer",[161,162,163,164,165,166,167,168],"colorectal cancer","metastatic colorectal cancer","pMMR\u002FMSS","sintilimab","PD-1 inhibitor","gossypol acetate","LRPPRC","immunotherapy","2026-06-22",{"date":171,"type":37},"2026-06-25",{"date":144,"type":22},{"date":174,"type":22},"2029-09-15",{"name":43,"class":44},{"id":177,"slug":4,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100643933","NCT07669675","TPO-RA Plus Baricitinib vs. TPO-RA for ITP","TPO-RA Plus Baricitinib vs. TPO-RA in Patients With ITP : A Randomized, Open-label Trial","Inclusion Criteria:\n\n1. ≥18 years old;\n2. Patients diagnosed with primary ITP who failed to achieve a response after 14 days of full-dose TPO-RA therapy;\n3. Patients with baseline platelet count less than 30×10⁹\u002FL, or those with baseline platelet count ranging from 30×10⁹\u002FL to 50×10⁹\u002FL accompanied by clinically significant bleeding (WHO bleeding score ≥2).\n\nExclusion Criteria:\n\n* Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant;\n* With active malignancy or a history of malignant tumor;\n* Having experienced severe bacterial, viral, fungal or parasitic infection within the past 4 weeks;\n* With a history of symptomatic herpes zoster infection within 12 weeks prior to screening;\n* Active or chronic HBV, HCV or HIV infection;\n* Evidence of active tuberculosis; or previous evidence of active tuberculosis without appropriate and documented treatment; or household contact with patients with active tuberculosis without appropriate and documented tuberculosis prophylaxis;\n* Receipt of live vaccines within the past 12 weeks, or planned live vaccination during the study period;\n* Prior baricitinib therapy;\n* History of solid organ transplant or planned surgery;\n* Myelodysplastic syndrome, aplastic anemia or myelofibrosis;\n* Patients with other diseases were undergoing treatment with immunosuppressants;\n* Clinically significant thromboembolic events within the past 24 weeks, or ongoing anticoagulant treatment, who are deemed ineligible for the study by the investigator;\n* History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure;\n* History or active manifestations of severe or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, neurological, neuropsychiatric, or other medical conditions that, in the investigator's judgment, could confer unacceptable safety risks with the investigational product or confound the interpretation of study data;\n* AST \\> 2 times the upper limit of normal (ULN), ALT \\> 2×ULN, TBIL ≥ 1.5×ULN;\n* eGFR \\\u003C 50 mL\u002Fmin\u002F1.73m²;\n* Other patients deemed unsuitable for enrollment in this study by the investigator.",{"count":183,"type":22},100,[25],"This is a prospective, randomized, controlled trial. ITP patients who failed prior full-does TPO-RA monotheray for 14 days. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone. The primary endpoint was the 14-day overall response rate without any rescue therapy.",[187],"ITP - Immune Thrombocytopenia",[189,190,191],"immune thrombocytopenia","baricitinib","TPO-RA","2026-06-20",{"date":171,"type":37},{"date":195,"type":22},"2026-07-01",{"date":197,"type":22},"2028-08-31",{"name":43,"class":44},{"id":200,"slug":4,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":45},"100644385","NCT07662525","Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP","Atorvastatin Combined With N-Acetyl-L-Cysteine Plus Romiplostim for Management of Steroid-Resistant\u002FRelapsed Immune Thrombocytopenia","Inclusion Criteria:\n\n* Diagnosed with primary ITP;\n* Aged ≥18 years;\n* Patients with treatment failure or relapse after first-line corticosteriod therapy for ITP;\n* Platelet count \\\u003C30×10⁹\u002FL.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant;\n* Presence of active malignant tumors;\n* Active HBV, HCV or HIV infection;\n* Active infection requiring systematic treatment;\n* Leukemia, myelodysplastic syndrome, aplastic anemia, myelofibrosis or other hematological disorders that may cause thrombocytopenia;\n* History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure;\n* AST \\> 2 times the upper limit of normal (ULN), ALT \\> 2×ULN, or TBIL ≥ 1.5×ULN;\n* eGFR \\\u003C 50 mL\u002Fmin\u002F1.73m²;\n* Any other subjects deemed ineligible for enrollment by the investigator.",{"count":206,"type":22},50,[57],"This is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in adult patients with ITP following CS failure.",[210],"Immune Thrombocytopenic Purpura",[189,212,213,214,215],"atorvastatin","N-acetyl-L-cysteine","romiplostim","sustained response off-treatment","2026-06-19",{"date":218,"type":37},"2026-06-23",{"date":220,"type":22},"2026-06-01",{"date":222,"type":22},"2028-12-30",{"name":43,"class":44},{"id":225,"slug":4,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":19,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":45},"100641170","NCT07574346","IASO207 Injection in the Treatment of Relapsed\u002FRefractory B-cell Malignancies","A Single-arm, Dose-escalation Clinical Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of IASO207 Injection in Subjects With Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years old and ≤ 75 years old.\n* 2\\. Previously diagnosed by histopathological biopsy as one of the following pathological types:\n\n  1. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS); high-grade B-cell lymphoma (HGBL);\n  2. DLBCL transformed from indolent lymphoma, including transformation from follicular lymphoma (FL) or marginal zone lymphoma (MZL), and DLBCL transformed from CLL\u002FSLL (Richter transformation);\n  3. Grade 3B follicular lymphoma (FL3B); primary mediastinal large B-cell lymphoma (PMBCL).\n* 3\\. Recurrent\u002Frefractory B-cell lymphoma patients who have failed standard treatment (including recurrence, non-response, progression) must have received a standard immunotherapy regimen containing CD20 monoclonal antibody and anthracycline drugs:\n\n  * Recurrent disease refers to the occurrence of disease recurrence or progression ≥ 12 months after treatment;\n  * Refractory disease refers to disease progression during treatment or best response of disease stability (SD), or recurrence within 12 months after autologous hematopoietic stem cell transplantation, or disease progression within 12 months after treatment.\n* 4\\. Before enrollment, it is confirmed that CD19 target expression is positive:\n\n  1. Previous pathological results indicate positive CD19 expression, and\u002For;\n  2. Can provide archived or fresh puncture specimens to the central laboratory for detection to confirm positive CD19 expression.\n* 5\\. According to the Lugano 2014 standard, there is at least one measurable lesion (lymph node lesion LDi \\> 1.5 cm, extranodal lesion LDi \\> 1.0 cm);( LDi is longest diameter)\n* 6\\. ECOG score 0-2;\n* 7\\. Expected survival period ≥ 12 weeks;\n* 8\\. Screening period examination confirms appropriate organ function: i. Blood routine: absolute neutrophil count (ANC) ≥ 1×109\u002FL; platelets (PLT) ≥ 50×109\u002FL; hemoglobin (Hb) ≥ 70g\u002FL (must not have received any G-CSF\u002FGM-CSF treatment or red blood cell and platelet transfusion within 7 days before laboratory examination); ii. Peripheral blood T lymphocyte absolute count ≥ 300 cells\u002FμL; iii. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× upper limit of normal (ULN); serum total bilirubin ≤ 1.5× ULN (for patients with tumor liver metastasis: ALT\u002FAST ≤ 5× ULN; TBil ≤ 3× ULN); iv. Cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%; v. Pulmonary function: oxygen saturation at rest ≥ 91%; vi. Renal function: calculated creatinine clearance rate (CrCl) ≥ 40 ml\u002Fmin according to Cockcroft-Gault formula; vii. Coagulation function: fibrinogen ≥ 1.0g\u002FL; activated partial thromboplastin time (aPTT) ≤ 1.5× ULN, prothrombin time (PT) ≤ 1.5× ULN;\n* 9\\. Pregnant participants should agree to take effective contraceptive measures or drugs from the date of signing the informed consent form until at least 1 year after the last administration of IASO207 injection.\n\nExclusion Criteria:\n\n* 1\\. There is invasion of central nervous system tumors; and\u002For primary central nervous system DLBCL, primary testicular LBCL.\n* 2\\. The tumor involves the small intestine, colon, and\u002For imaging examination indicates that the tumor involves the sub-mucosal layer of the gastrointestinal tract, and the patient has been evaluated to have a risk of organ perforation.\n* 3\\. Within the past 5 years before screening, the subject has had other malignant tumors except for the disease under study, excluding cervical carcinoma in situ after radical treatment, basal cell or squamous cell skin cancer after radical treatment, local prostate cancer, breast duct carcinoma in situ or thyroid papillary carcinoma.\n* 4\\. Infectious disease screening meets one of the following conditions: i. The subject has positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and abnormal peripheral blood HBV DNA test (abnormal HBV DNA test is defined as: HBV DNA quantitative test higher than the detection center's lower limit or higher than the normal reference range of the detection center or HBV DNA qualitative test positive); ii. The subject has positive hepatitis C virus (HCV) antibody and positive peripheral blood HCV RNA; iii. The subject has positive human immunodeficiency virus (HIV) antibody; iv. The subject has syphilis; v. The subject is an active CMV infection patient.\n* 5\\. Before enrollment, there is uncontrollable active bacterial, fungal or viral infection: i. There are persistent symptoms\u002Fsigns related to infection that require intravenous anti-infection drug treatment; ii. After appropriate anti-infection treatment, the clinical symptoms and examinations do not indicate improvement.\n* 6\\. Severe heart disease: including but not limited to unstable angina pectoris, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA functional classification standard ≥ III), severe arrhythmia.\n* 7\\. Within the past 6 months before screening, the subject has had central nervous system diseases or histories, such as epilepsy, paralysis, aphasia, cerebral infarction, cerebral hemorrhage, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome (such as cerebral aneurysm, epilepsy, stroke \\[except lacunar infarction\\], senile dementia, psychosis, etc.) or patients with consciousness disorders.\n* 8\\. The subject has received any CD19-targeted treatment before.\n* 9\\. The subject has received any allogeneic hematopoietic stem cell transplantation (Allo-HSCT), autologous CAR-T and other allogeneic donor cell adoptive therapy.\n* 10\\. The subject with a large mass (diameter of the lesion \\> 7.5 cm) is not included in this study; patients whose disease progresses too rapidly and is expected not to benefit from the treatment of this study will not be included in this study.\n* 11\\. Before enrollment, the subject does not meet the drug\u002Ftreatment washout period: i. The subject needs or is continuously using systemic corticosteroids or other immunosuppressants within 4 weeks before enrollment; ii. The subject has received bispecific antibody, autologous hematopoietic stem cell transplantation, autologous CAR-T treatment within 12 weeks before enrollment; iii. The subject has received radiotherapy or grade 4 major surgery within 4 weeks before enrollment; or plans to undergo general anesthesia surgery within 12 weeks after receiving the study treatment.\n\niv. Using monoclonal antibodies, cytotoxic chemotherapy, or ADC drugs within 4 weeks prior to enrollment; v. Having received vaccination or any off-label clinical study drug treatment within 4 weeks prior to enrollment.\n\n* 12\\. Judged by the investigator, there are other unstable systemic diseases: including but not limited to severe liver, kidney or metabolic diseases that require treatment.\n* 13\\. The adverse reactions caused by previous anti-tumor treatment have not been alleviated to ≤ grade 2 (NCI-CTCAE v5.0 version).\n* 14\\. Those with a history of allergic reactions to the excipient components of IASO207 injection.\n* 15\\. Those who have received solid organ transplantation in the past.\n* 16\\. Pregnant or lactating women.\n* 17\\. Other situations deemed by the investigator as not suitable for enrollment.",{"count":231,"type":22},18,[233],"EARLY_PHASE1","This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of IASO207 Injection in patients with Relapsed\u002FRefractory B-cell Malignancies。",[236],"Malignancies",[238,239,240,241],"Relapsed","Refractory","B-cell malignancies","IASO207","2026-06-16",{"date":244,"type":37},"2026-06-18",{"date":246,"type":37},"2026-05-29",{"date":248,"type":22},"2042-04-30",{"name":43,"class":44},{"id":251,"slug":4,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":76,"minAge":256,"maxAge":132,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":266,"locationsCount":4},"100544087","NCT06364319","Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD","Study on the Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD) of the Liver Following Allogeneic Hematopoietic Stem Cell Transplantation.","Inclusion Criteria:\n\n1. Age 16 and 65 years\n2. Received allogeneic hematopoietic stem cell transplantation\n3. Developed chronic GVHD in the liver after transplantation\n4. Ineffective prednisone treatment prior to screening\n5. Received ≤4 lines of systemic therapy prior to screening\n6. After informed consent, the patient agreed to receive anti-CD25 rhMAb treatment\n\nExclusion Criteria:\n\n1. Elevation of bilirubin, ALT, or alkaline phosphatase due to reasons other than chronic GVHD\n2. No prior treatment with prednisone\n3. Overlap syndrome\n4. Uncontrolled active infection\n5. Organ failure\n6. Early progression or recurrence of hematologic diseases\n7. Allergy to anti-CD25 rhMAb\n8. Received other interleukin-2 receptor monoclonal antibody treatment due to various reasons within one month after transplantation\n9. Participated in other clinical studies within one month","16 Years",{"count":258,"type":22},30,[80],"The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation. After obtaining informed consent, the patients will receive a treatment regimen consisting of the Anti-CD25 rhMAb in combination with prednisone, cyclosporine, and ruxolitinib.The objective is to assess the effectiveness and safety of Anti-CD25 rhMAb in the treatment of severe chronic GVHD affecting the liver.",[262],"cGVHD",{"date":244,"type":37},{"date":144,"type":22},{"date":146,"type":22},{"name":43,"class":44},{"id":268,"slug":4,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":45},"100642119","NCT07653711","Coated Aldehyde Oxystarch for Protein-Bound Uremic Toxin Reduction in End-Stage Renal Disease","An Exploratory, Single-Center, Self-Controlled Trial of Coated Aldehyde Oxystarch for Reducing Protein-Bound Uremic Toxins in Patients With End-Stage Renal Disease","Inclusion Criteria:\n\n* Age ≥ 18 years, no restriction on sex or ethnicity.\n* Receiving maintenance dialysis for at least 3 months, with dialysis regimen remaining unchanged during the trial period.\n* If taking other medications that do not interfere with gut microbiota prior to enrollment, they must have been stable for at least 1 month and the regimen must remain unchanged during the trial.\n* Ability to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Known allergy to Coated Aldehyde Oxystarch.\n* History of or planned kidney transplantation within 6 months, or change in dialysis regimen.\n* Use of medications or supplements that may affect gut microbiota (e.g., antibiotics, probiotics, prebiotics, laxatives) within the past 3 months.\n* Diagnosis of serious gastrointestinal diseases, including gastrointestinal bleeding, colitis, inflammatory bowel disease, irritable bowel syndrome, history of intestinal obstruction, history of gastrectomy or duodenectomy.\n* History of cardiovascular or cerebrovascular events within 3 months prior to screening, including hospitalization for stroke, myocardial infarction, unstable angina, congestive heart failure; severe valvular stenosis, uncontrolled atrial fibrillation or arrhythmia; QTc interval \\>500 ms on repeated ECG.\n* Concurrent severe primary diseases of cardiovascular, cerebrovascular, hepatic, hematopoietic systems, or other known life-threatening diseases (e.g., malignancy, AIDS), or patients with mental or legal disabilities.\n* Investigator judges life expectancy ≤6 months.\n* Inability to maintain stable dietary habits during the study period.\n* Inability to maintain original dialysis regimen during the study period.\n* Use of Chinese patent medicines for kidney disease (e.g., Shenkang Injection, Haikun Shenxi Capsule, Shenshuaining, Tripterygium preparations, Niaoduqing Granules) within 1 month prior to enrollment.\n* Participation in another clinical trial within the past 1 month.\n* Intellectual disability, psychiatric disorders, or suspected\u002Fconfirmed history of alcohol or drug abuse that may affect compliance.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.",{"count":258,"type":22},[57],"The goal of this clinical trial is to learn if Coated Aldehyde Oxystarch (Xiqing) works to reduce protein-bound uremic toxins (PBUTs) in adults with end-stage renal disease (ESRD). It will also learn about the safety of Coated Aldehyde Oxystarch. The main questions it aims to answer are:\n\nDoes Coated Aldehyde Oxystarch lower the blood levels of protein-bound uremic toxins, such as indoxyl sulfate and p-cresyl sulfate?\n\nWhat medical problems do participants have when taking Coated Aldehyde Oxystarch?\n\nResearchers will compare the levels of PBUTs before treatment (baseline) with those after treatment with Coated Aldehyde Oxystarch to see if it works to reduce these toxins.\n\nParticipants will:\n\nTake Coated Aldehyde Oxystarch (Xiqing) 10 capsules per time, three times daily (each capsule 0.625 g, total daily dose 18.75 g) for 3 months.\n\nVisit the clinic every month for checkups and blood tests.\n\nProvide blood samples to measure protein-bound uremic toxin levels and routine safety parameters.",[277],"End Stage Renal Disease on Dialysis","2026-06-12",{"date":280,"type":37},"2026-06-17",{"date":282,"type":37},"2025-04-21",{"date":284,"type":22},"2026-08",{"name":43,"class":44},{"id":287,"slug":4,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":76,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":295,"phases":4,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":311},"100642346","NCT07640997","Real-world Study of Aflibercept 8 mg in nAMD","REFLECTION-An Observational Study Program to Investigate the Effectiveness of Aflibercept 8 mg Used in Neovascular Age-related Macular Degeneration (nAMD) in a Real-world Setting.","Inclusion Criteria:\n\n* Patient aged ≥50 years\n* A diagnosis of nAMD\n* Signed informed patient consent before the start of data collection\n* Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice\n\nExclusion Criteria:\n\n* Participation in an investigational program with interventions outside of clinical routine practice\n* Contraindications as listed in the intravitreal aflibercept 8 mg local product information (Ocular or periocular infections, severe active intraocular inflammation, and known allergy to aflibercept or any of its excipients)\n* The fellow eye has received intravitreal anti-VEGF treatment other than aflibercept within 28 days prior to enrollment\n* Intraocular pressure (IOP) in the study eye \\> 25 mmHg\n* Additional exclusion criteria for naïve nAMD patients:\n\n  * Any prior ocular treatment in the study eye or systemic treatment for nAMD\n* Additional exclusion criteria for pretreated nAMD patients:\n\n  * Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days\n  * Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months\n  * Dexamethasone implant in the study eye within the last 6 months\n  * Any concurrent drug releasing implant in the study eye","50 Years",{"count":294,"type":22},300,"OBSERVATIONAL","The goal of this observational study is to explore the effectiveness of aflibercept 8 mg in treating both treatment-naive and previously treated patients with neovascular age-related macular degeneration (nAMD) in a real-world setting. The main questions it aims to answer are:\n\nWhat are the short-term and long-term efficacy outcomes of aflibercept 8 mg in treatment-naive or previously treated nAMD patients? What are the safety characteristics and the treatment patterns of aflibercept 8 mg in these patient populations?\n\nParticipants will:\n\nReceive aflibercept 8 mg as part of their clinical treatment for nAMD. Undergo assessments to evaluate both the efficacy and safety of the treatment over the short and long term.\n\nProvide data on their visual acuity (BCVA) changes at multiple follow-up points (4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months).\n\nReport any adverse events and treatment patterns during the study period. Have their central subfield thickness (CST) measured at specified intervals. This study will help inform clinical practices regarding the use of aflibercept in nAMD patients and contribute to understanding its effectiveness and safety in real-world settings.",[298],"Neovascular Age-Related Macular Degeneration (nAMD)",[300,301,302],"nAMD","Aflibercept 8mg","Real World Evidence","2026-06-10",{"date":305,"type":37},"2026-06-11",{"date":307,"type":37},"2025-11-11",{"date":309,"type":22},"2027-12-31",{"name":43,"class":44},27,{"id":313,"slug":4,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":321,"studyType":295,"phases":4,"briefSummary":322,"conditions":323,"keywords":327,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":339,"leadSponsor":341,"locationsCount":45},"100641818","NCT07647692","Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT","Development and Multi-Cohort Validation of a Deep Learning Spatiotemporal Model for Predicting Long-Term Progression of Pulmonary Ground-Glass Nodules Using Serial Thoracic CT","GGN-Trajectory","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Persistent pulmonary ground-glass nodule (pGGN or mGGN, 5-30 mm) on thin-slice chest CT (slice thickness ≤ 1.5 mm).\n* Baseline and follow-up thin-slice chest CTs of sufficient quality for 3D segmentation and registration.\n* Minimum interval between any two consecutive CTs \\> 1 month.\n* Complete baseline clinical data available (age, sex, smoking history, family history of malignancy, relevant comorbidities).\n\nCohort-specific inclusion\n\n* Group 1 (Development): surgical resection of the target GGN at PKUPH between Jan 2007 - Jun 2025, with ≥ 2 pre-operative thin-slice CTs available.\n* Group 2 (Surgical internal test): surgical resection at PKUPH between Jul 2025 - Jan 2026, with ≥ 2 pre-operative thin-slice CTs available.\n* Group 3 (Non-surgical internal test): non-operative management at PKUPH between Jan 2020 - Dec 2025, with ≥ 3 thin-slice CTs of the target GGN available.\n* Group 4 (Prospective external validation): prospective enrollment after model lock at participating centers, baseline CT plus ≥ 2 planned routine follow-up thin-slice CTs.\n\nExclusion Criteria:\n\n* Coexisting severe pulmonary disease that obscures evaluation of the target GGN (e.g., active pulmonary tuberculosis, severe interstitial lung disease).\n* Prior history of any other thoracic malignancy, or active extrathoracic malignancy under treatment within 5 years, that would confound interpretation of the target GGN.\n* CT image quality insufficient for registration and feature extraction (severe motion artifact, slice thickness \\> 1.5 mm at any required timepoint, or extensive metallic artifact projecting over the target GGN).\n* Pure solid nodule with no ground-glass component.\n* Target GGN already received treatment (resection, ablation, or radiotherapy) prior to the baseline CT used in this study.",{"count":320,"type":22},4750,"5 Years","Pulmonary ground-glass nodules (GGNs) are commonly found on chest CT scans. Some stay stable for years, while others slowly or rapidly turn into lung cancer. Doctors currently follow these nodules with repeated CT scans, but it is difficult to tell ahead of time which nodules will progress, how fast they will progress, and which ones can be safely monitored rather than immediately treated.\n\nThis observational study aims to develop and validate an artificial intelligence (AI) model that uses each patient's series of CT scans over time to predict the long-term growth behavior of a GGN. The research team will collect three retrospective single-center cohorts from Peking University People's Hospital (a development cohort and two internal test cohorts, one from surgically resected patients and one from non-operated patients followed by serial CT) as well as a prospective multi-center validation cohort enrolled after the AI model is locked.\n\nFor every patient, each GGN is automatically segmented in three dimensions on every CT scan. A deep learning model extracts imaging features at each timepoint and feeds the sequence of features, together with the actual times between scans, into a time-aware sequence model. The model is trained to predict (i) whether the nodule will show radiological progression at 1, 3, and 5 years after baseline, and (ii) which of four long-term growth patterns the nodule will follow: stable, slow progression, slow-then-rapid progression, or rapid progression. In patients who were ultimately resected, the histopathological diagnosis serves as a secondary reference standard.\n\nThis is an observational study. No experimental treatment is given. All CT scans and clinical visits are part of routine clinical care.",[324,325,326],"Pulmonary Nodules","Lung Neoplasms","Adenocarcinoma of Lung",[328,329,330,331,332,333,334,335],"Ground Glass Opacity","Ground-Glass Nodule","Longitudinal CT","Time-Series Analysis","Growth Trajectory","Volume Doubling Time","Deep Learning","Radiomics",{"date":337,"type":37},"2026-06-15",{"date":220,"type":22},{"date":340,"type":22},"2031-06-01",{"name":43,"class":44},{"id":343,"slug":4,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":52,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":295,"phases":4,"briefSummary":350,"conditions":351,"keywords":356,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":4},"100643796","NCT07598084","Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement","Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI: Development and Clinical Validation of a Diffusion-Weighted Imaging-Based Synthetic Contrast-Enhanced MRI System for Non-Contrast Breast Cancer Diagnosis and Risk Stratification","Inclusion Criteria:\n\n1. Complete breast MRI data;\n2. Negative pathology biopsy results or negative follow-up examinations for at least 12 months for non-cancer cases;\n3. Positive biopsy results that meet the requirements for the pathological subtype of cancer for cancer cases;\n4. Original data that can be used to verify clinical status, including radiological and pathological reports;\n\nExclusion Criteria:\n\n1. Partial mastectomy or puncture biopsy on the diseased side of the breast prior to breast MRI examination;\n2. Poor image quality;\n3. Implants in the affected breast;",{"count":349,"type":22},12000,"This study is conducted under the ethics-approved project titled \"Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI''.The goal of this observational study is to develop an integrated breast MRI system that uses diffusion-weighted imaging (DWI) to create synthetic contrast-enhanced images. This system aims to diagnose and screen for breast cancer without the need for contrast agents, while using a generated risk score to perform imaging-based triage and risk stratification.\n\nParticipants will include people aged 18 and older who require a breast MRI either for evaluation of a suspicious finding or for high-risk screening.\n\nThis study seeks to answer two main questions:\n\n* Can synthetic contrast-enhanced images generated from DWI match real contrast-enhanced images in their ability to distinguish benign from malignant breast lesions?\n* Can the risk score derived from DWI-based synthetic images enable imaging-level risk stratification, allowing people at lower risk to avoid contrast agent injection? Researchers will compare the quality of synthetic images against real contrast-enhanced images and will recruit radiologists to assess how well these images perform for diagnostic and screening tasks. MRI data from participants undergoing breast MRI will be used to train, validate, and test this integrated system.",[352,353,354,355,334],"Breast Neoplasms","Artificial Intelligence (AI)","Magnetic Resonance Imaging (MRI)","Diffusion Magnetic Resonance Imaging",[357,358,359,360],"Breast","Magnetic Resonance Imaging","Artificial Intelligence","Deep learning","2026-06-05",{"date":363,"type":37},"2026-06-09",{"date":365,"type":22},"2026-06",{"date":367,"type":22},"2027-05",{"name":43,"class":44},{"id":370,"slug":4,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":76,"minAge":132,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":385,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":45},"100643642","NCT07632664","Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients","A Multicenter Clinical Study on a New Treatment Model Combining New Surgical Techniques, Perioperative Comprehensive Treatment, and Postoperative Rehabilitation for Elderly Patients With Lung Cancer","Inclusion Criteria:\n\n1. Aged ≥65 years old\n2. Pathologically confirmed non-small cell lung cancer with clinical stage eligible for curative surgical resection\n3. Complete preoperative geriatric comprehensive assessment data available\n4. Capable of finishing planned surgery and long-term follow-up\n5. Voluntarily sign informed consent form\n\nExclusion Criteria:\n\n1. History of other malignant tumors within recent 5 years\n2. Severe organic dysfunction of heart, liver, renal or respiratory system that cannot tolerate thoracic surgery\n3. Preoperative confirmed distant metastasis preventing radical resection\n4. Uncontrolled active severe infection or obvious coagulation disorders\n5. Severe psychiatric disorder or cognitive dysfunction failing to cooperate with treatment and follow-up\n6. Refuse random grouping and postoperative regular monitoring",{"count":376,"type":22},1000,[57],"This multicenter prospective clinical study focuses on elderly patients with lung cancer. We will build a standardized clinical registry database, develop perioperative risk stratification and surgical early-warning models, optimize individualized surgical regimens, construct multidisciplinary perioperative comprehensive therapy, integrated Chinese-Western medicine full-cycle management and personalized postoperative rehabilitation systems, so as to form a whole-process optimized treatment model for elderly lung cancer.",[380,381,382,383,384],"Lung Neoplasm","Thoracic Surgical Procedures","Perioperative Care","Postoperative Rehabilitation","Aged",[386],"Elderly lung cancer, Risk stratification, Multimodality therapy, Integrated Chinese and Western Medicine, Enhanced recovery after surgery","2026-06-02",{"date":389,"type":37},"2026-06-08",{"date":391,"type":37},"2024-08-01",{"date":197,"type":22},{"name":43,"class":44},{"id":395,"slug":4,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":76,"minAge":4,"maxAge":4,"enrollmentInfo":400,"targetDuration":321,"studyType":295,"phases":4,"briefSummary":402,"conditions":403,"keywords":408,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":45},"100620547","NCT07359040","Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","Inclusion Criteria:\n\nPatients with non-small cell lung cancer (Stage IB-IIIB) who require radical surgery following neoadjuvant therapy.\n\nExclusion Criteria:\n\n1. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems;\n2. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC);\n3. Pregnancy or lactation;\n4. Insufficient sample quality;\n5. Severe organ dysfunction (e.g. cardiac or renal insufficiency);\n6. Other judgments by the Investigator that the patient should not participate in the study.",{"count":401,"type":22},80,"This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1\u002FVEGF bispecific antibody, with those of conventional PD-1 inhibitors. Beyond evaluating its direct therapeutic benefits, this research also seeks to elucidate the potential mechanisms underlying the enhanced efficacy of Ivonescimab. Additionally, the study will conduct secondary exploratory analyses, including the identification and validation of predictive and prognostic biomarkers, as well as multi-omics profiling to investigate the molecular mechanisms of action. Collectively, these efforts aim to provide comprehensive experimental data to support the rational clinical application of Ivonescimab and the development of precision medicine strategies for NSCLC.",[404,405,406,407],"Non-Small Cell Lung Cancer","Neoadjuvant Therapy","PD-1 Inhibitors","Immunotherapy",[409,410,404],"Neoajuvant therapy","Ivonescimab",{"date":412,"type":37},"2026-06-03",{"date":414,"type":37},"2025-07-01",{"date":416,"type":22},"2027-10-30",{"name":43,"class":44},{"id":419,"slug":4,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":425,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":434,"leadSponsor":435,"locationsCount":4},"100638952","NCT07629947","Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia","A Randomized Controlled Trial Comparing Different Graft Sources for Haploidentical Transplantation in Aplastic Anemia","PB-Graft Haplo","Inclusion Criteria:\n\nPatients with newly diagnosed or relapsed severe aplastic anemia (SAA) or very severe aplastic anemia (vSAA) according to the Camitta criteria. SAA is defined as bone marrow cellularity \\\u003C25% and at least two of the following peripheral blood criteria: absolute neutrophil count \\\u003C0.5 × 10⁹\u002FL, platelet count \\\u003C20 × 10⁹\u002FL, or reticulocyte count \\\u003C20 × 10⁹\u002FL. vSAA is defined as SAA with an absolute neutrophil count \\\u003C0.2 × 10⁹\u002FL.\n\nAge 18 to 40 years. Availability of a haploidentical related donor. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n\nAdequate organ function, defined as:\n\nCardiac function: left ventricular ejection fraction ≥50% and no severe arrhythmia; Hepatic function: total bilirubin ≤2 times the upper limit of normal and alanine aminotransferase\u002Faspartate aminotransferase ≤3 times the upper limit of normal; Renal function: creatinine clearance ≥60 mL\u002Fmin. No active infection. For women of childbearing potential, a negative pregnancy test is required. All patients must agree to use effective contraception during the study period.\n\nWritten informed consent provided by the patient or legal representative.\n\nExclusion Criteria:\n\nPresence of hematologic malignancy or myelodysplastic syndrome-related chromosomal abnormalities, such as +8 or del(7q).\n\nPrior allogeneic hematopoietic stem cell transplantation or prior organ transplantation.\n\nAvailability of an HLA-matched sibling donor. Active uncontrolled infection, including unresolved invasive fungal disease, active tuberculosis, sepsis, or other uncontrolled infections.\n\nSevere comorbidities, defined as Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score ≥4, or uncontrolled autoimmune disease.\n\nDonor-related contraindications, including donor age \\\u003C12 years or \\>65 years, donor body mass index \\\u003C18 or \\>35 kg\u002Fm², contraindications to anesthesia, or contraindications to bone marrow harvest.\n\nPsychiatric illness that prevents cooperation with the study procedures, or any condition considered by the investigator to make the patient unsuitable for study participation.","40 Years",{"count":427,"type":22},180,[57],"Severe aplastic anemia is a life-threatening bone marrow failure disorder. Haploidentical hematopoietic stem cell transplantation has become an important curative treatment option for patients who do not have an HLA-matched sibling donor.\n\nTraditionally, haploidentical transplantation for severe aplastic anemia uses a graft composed of granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells. However, bone marrow collection is invasive and may increase donor burden. Peripheral blood stem cell collection is simpler and less invasive, but it remains unclear whether using peripheral blood stem cells alone provides similar clinical outcomes without increasing the risk of graft-versus-host disease.\n\nThis multicenter, randomized, open-label, non-inferiority trial will compare granulocyte colony-stimulating factor-primed peripheral blood stem cells alone with granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells as graft sources for haploidentical transplantation in patients with severe or very severe aplastic anemia. Participants will be randomly assigned in a 1:1 ratio to either graft source group. The primary outcome is the cumulative incidence of grade II-IV acute graft-versus-host disease within 100 days after transplantation. Secondary outcomes include engraftment, chronic graft-versus-host disease, infections, immune reconstitution, survival, and donor safety.",[431],"Severe Aplastic Anemia (SAA)",{"date":361,"type":37},{"date":337,"type":22},{"date":41,"type":22},{"name":43,"class":44},{"id":437,"slug":4,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":52,"sex":76,"minAge":18,"maxAge":19,"enrollmentInfo":441,"targetDuration":4,"studyType":295,"phases":4,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":4},"100636348","NCT07564518","Application of FreeStyle Libre 2 for Evaluating Glycemic Variability Characteristics in Patients With Extreme Glucose Metabolism Phenotypes","1. Inclusion Criteria:\n\n   1. Group A1:\n\n      * Age ≥ 18 years;\n      * Patients with β cell dysfunction monogenic diabetes confirmed by DNA sequencing or other diagnostic testing.\n   2. Group A2:\n\n      * Age ≥ 18 years;\n      * Patients with confirmed type 2 diabetes mellitus;\n      * Derived from this center's existing continuous glucose monitoring (CGM) database.\n   3. Group B1:\n\n      * Age ≥ 18 years;\n      * Normal fasting plasma glucose (≥ 3.6 and \\\u003C 6.1 mmol\u002FL) and normal 2-hour plasma glucose during OGTT (≥ 3 and \\\u003C 7.8 mmol\u002FL);\n      * Fasting insulin ≥ 25 µU\u002FmL and\u002For 2-hour insulin during OGTT greater than 10 times the fasting insulin level.\n   4. Group B2:\n\n      * Age ≥ 18 years;\n      * Normal glucose tolerance meeting the 2024 ADA criteria: fasting plasma glucose \\\u003C 5.6 mmol\u002FL, 2-hour plasma glucose during OGTT \\\u003C 7.8 mmol\u002FL;\n      * According to laboratory reference standards, fasting insulin ≥ 2.6 and \\\u003C 25 µU\u002FmL, and 2-hour insulin during OGTT 5-10 times the fasting insulin level.\n      * Derived from this center's existing continuous glucose monitoring (CGM) database.\n2. Exclusion Criteria:\n\n   1. Neonates younger than 4 months of age (congenital diabetes);\n   2. Pregnancy;\n   3. Patients with positive pancreatic autoantibody test results;\n   4. Patients with severe cardiovascular or cerebrovascular diseases, hepatic disease, or renal disease;\n   5. Patients who have participated in other clinical trials.",{"count":134,"type":22},"This cross-sectional study aims to further subdivide diabetes mellitus into more homogeneous subgroups by focusing on extreme glucose metabolism phenotypes, including monogenic diabetes with β cell dysfunction, hyperinsulinemia caused by excessive β cell secretion, and postprandial hypoglycemia phenotypes. By utilizing continuous glucose monitoring (CGM) technology and the FreeStyle Libre 2 glucose monitoring device, this study will evaluate glycemic variability patterns in patients with extreme glucose metabolism phenotypes and perform comparative analyses using existing CGM data from healthy populations and patients with type 2 diabetes in our center's database. The study aims to address current gaps in understanding glycemic variability characteristics under extreme β cell functional states, provide novel dynamic monitoring evidence to support early identification, precise classification, and personalized management of these special metabolic states, and simultaneously screen for biomarkers to enable more accurate disease identification, thereby offering potential avenues for improving personalized treatment of diabetes mellitus.",[444,445],"Monogenic Diabetes","Hyperinsulinemia","2026-05-31",{"date":387,"type":37},{"date":449,"type":22},"2026-05-25",{"date":451,"type":22},"2027-01-09",{"name":43,"class":44},{"id":454,"slug":4,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":76,"minAge":459,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":295,"phases":4,"briefSummary":462,"conditions":463,"keywords":466,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":477,"locationsCount":45},"100638305","NCT07620431","Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma","An Observational Study on the Safety and Efficacy of Neoadjuvant Concurrent Chemoradiotherapy Sequential Surgery for High-Risk Localized Ewing Sarcoma","Inclusion Criteria:\n\n1. The subject or their legal representative signs the written informed consent prior to enrollment.\n2. Age \\\u003C= 55 years old.\n3. Histologically confirmed Ewing sarcoma, with FET family (including EWSR1 or FUS) gene rearrangement confirmed by FISH or NGS. Clear FET-non ETS fusion cases are excluded.\n4. Deemed difficult to achieve a satisfactory surgical margin by 2 or more senior musculoskeletal oncologists.\n5. ECOG Performance Status: 0-1.\n6. Expected life expectancy \\>= 3 months.\n7. Women of childbearing potential must have a negative pregnancy test within 1 week prior to enrollment and agree to use contraception; male subjects must agree to use contraception or have undergone surgical sterilization during the study.\n\nExclusion Criteria:\n\n1. No opportunity for surgical resection after neoadjuvant chemotherapy.\n2. Extensive metastasis with no indication for local surgical resection.\n3. Uncontrolled concurrent medical conditions.\n4. Prior radiotherapy to the surgical site during front-line treatment.\n5. History of other malignant tumors within the past 5 years.\n6. Inability to cooperate with preoperative neoadjuvant radiotherapy (e.g., due to psychiatric factors).\n7. Any condition that, in the investigator's judgment, might harm the patient or prevent compliance with study requirements.","12 Months",{"count":461,"type":22},55,"This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery and postoperative chemotherapy in patients with high-risk, resectable localized Ewing sarcoma.",[464,465],"Ewing Sarcoma","Bone Neoplasms",[467,468,469,470,471],"Neoadjuvant Radiotherapy","Preoperative Radiotherapy","Observational Study","Local Control Rate","Wound Healing","2026-05-27",{"date":387,"type":37},{"date":220,"type":22},{"date":476,"type":22},"2027-12-01",{"name":43,"class":44},{"id":479,"slug":4,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":493,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":501,"locationsCount":45},"100632730","NCT07517484","Light and Anesthesia","Effects and Mechanisms of Ambient Light Intensity on the Depth of General Anesthesia","Inclusion Criteria:\n\n* a. Age between 18 and 65 years, regardless of gender;\n* b. ASA physical status I-II;\n* c. 18.5 ≤ BMI ≤ 28;\n* d. Signed written informed consent.\n\nExclusion Criteria:\n\n* a. Blindness or history of photosensitivity disorders;\n* b. Patients requiring medication for sleep, or with a history of sleep disorders;\n* c. Presence of neurological diseases;\n* d. Pregnancy;\n* e. Severe hepatic or renal dysfunction;\n* f. History of anesthetic drug abuse or alcohol abuse;\n* g. History of adverse anesthesia events (difficult airway, allergy to anesthetic agents).","64 Years",{"count":486,"type":22},66,[57],"The objective of this clinical trial is to investigate the effect of light exposure on sedation depth during general anesthesia.The primary research questions this study aims to address include:\n\nDoes light condition affect the dosage of anesthetic medications during anesthesia? By what mechanism does light exposure exert an influence on anesthesia? Participants will be randomly allocated to either the light-shielded group or the non-light-shielded group.Patients in the light-shielded group will wear an eye shield during anesthesia.\n\nThe following data will be recorded for all patients:\n\nInduction drug dosage Induction time Intraoperative anesthetic dosage Emergence time",[490,491,492],"Light","Anesthesia","Sedation",[494,495,496],"light","anesthesia","sedation depth",{"date":246,"type":37},{"date":499,"type":37},"2025-10-03",{"date":142,"type":22},{"name":43,"class":44},{"id":503,"slug":4,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":512,"conditions":513,"keywords":516,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":45},"100640378","NCT07617285","Allogeneic CAR-T(CT0890B) in NKG2DL+ R\u002FR AML","A Phase I Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Cells (CT0890B) in Patients With NKG2DL-Positive Relapsed\u002FRefractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Age 18-70 years (inclusive), male or female.\n2. Relapsed or refractory acute myeloid leukemia (R\u002FR AML) diagnosed according to the 2022 World Health Organization classification or ELN criteria, with confirmed NKG2D ligand-positive disease.\n3. Bone marrow blasts ≥5% by morphology.\n4. Estimated life expectancy \\>12 weeks.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n6. Adequate organ function without ongoing supportive care, defined as:\n\n   1. Cardiac: left ventricular ejection fraction (LVEF) ≥50%;\n   2. Hepatic: ALT and AST ≤2.5 × upper limit of normal (ULN), and total bilirubin ≤2 × ULN;\n   3. Renal: creatinine clearance ≥30 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n   4. Coagulation: activated partial thromboplastin time (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN.\n\n   c) Renal: creatinine clearance ≥30 mL\u002Fmin (calculated using the Cockcroft-Gault formula); d) Coagulation: activated partial thromboplastin time (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN.\n\nExclusion Criteria:\n\n1. Participants were diagnosed with acute promyelocytic leukemia (APL), BCR-ABL positive leukemia (chronic myeloid leukemia in acute phase), central nervous system leukemia;\n2. Participants with a history of epilepsy or other central nervous system disease;\n3. Participants who have previously received autologous or allogeneic CAR-T therapy;\n4. Participants who have received autologous stem cell transplantation or allogeneic stem cell transplantation within 12 weeks\n5. Participants who have received prior immunotherapy targeting NKG2DL;\n6. Participant has clinically significant active GVHD or is receiving systemic corticosteroids for GVHD;\n7. Participant has any of the following at screening:\n\n1)Active, uncontrolled systemic infection or requiring intravenous anti-infective agents 2)Any of the following cardiac conditions, including:\n\n1. New York Heart Association Class III-IV heart failure;\n2. History of myocardial infarction, coronary artery bypass grafting, or unstable angina within 6 months prior to Qinglin;\n3. History of uncontrolled arrhythmia of significant clinical significance (as judged by the investigator), such as ventricular arrhythmia;\n4. History of severe nonischemic ardiomyopathy;\n5. Other cardiac disease that the investigatorbelieve could jeopardize the participant 's well-being or compromise participation in this clinical trial; 3) Active bleeding of clinical significance as judged by the investigator; 4)Requiring supplemental oxygen to maintain oxygen saturation\\> 92%; 5)Patients with severe chronic obstructive pulmonary disease (COPD) or other lung diseases that cannot tolerate CAR-T treatment as judged by the investigator;","70 Years",{"count":311,"type":22},[511],"PHASE1","A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed\u002FRefractory Acute Myeloid Leukemia.",[514,515],"AML","Refractory\u002FRelapse Acute Myeloid Leukemia",[517,518,514],"CT0890B","Universal CAR-T","2026-05-23",{"date":220,"type":37},{"date":522,"type":22},"2026-05-07",{"date":41,"type":22},{"name":43,"class":44},{"id":526,"slug":4,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":19,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":541,"leadSponsor":543,"locationsCount":45},"100638640","NCT07617740","IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)","An Exploratory Clinical Study on the Treatment of Active Refractory Systemic Lupus Erythematosus With IASO207 Injection","Inclusion Criteria:\n\n1. Subjects aged 18-75 years old, regardless of gender.\n2. Subjects diagnosed with active refractory SLE: a) Confirmed by the 2019 European League Against Rheumatism (EULAR)\u002FAmerican College of Rheumatology (ACR) classification criteria or the 2012 Systemic Lupus Erythematosus Collaborative Clinic (SLICC) criteria for at least 24 weeks; b) SLE Disease Activity Index 2000 (SLEDAI-2K) score ≥ 8, with at least 1 organ system having a BILAG-2004 A-class activity score at screening, or 2 organ systems having a BILAG-2004 B-class activity score; c) Previously treated with standardized glucocorticoids and at least two immunosuppressants\u002Fadjusters, antimalarial drugs or biologics for at least 3 months.\n3. Positive for disease-related pathogenic antibodies: Anti-nuclear antibody (ANA) positive and\u002For anti-dsDNA positive and\u002For anti-Smith positive.\n4. Allowed to use ≤ 20mg\u002Fd prednisone or equivalent dose of corticosteroids at screening, and use at a stable dose for at least 2 weeks. Note: Local or inhaled corticosteroids (or its immunomodulators) can be used concurrently;\n5. If antimalarial treatment has been initiated for ≥ 12 weeks before screening and is used at a stable dose for at least 8 weeks, it is allowed to continue in the study (maximum hydroxychloroquine dose ≤ 400mg\u002Fd).\n6. If immunosuppressants have been used before screening, they must be used at a stable dose for at least 4 weeks.\n7. Laboratory tests must meet the following conditions: a) Blood routine: Absolute neutrophil count (ANC) ≥ 1.0×10\\^9\u002FL; Absolute lymphocyte count (ALC) ≥ 0.3×10\\^9\u002FL; Hemoglobin ≥ 60 g\u002FL; Platelets ≥ 50×10\\^9\u002FL b) Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× upper limit of normal (ULN); Serum total bilirubin ≤ 1.5×ULN (Gilbert's syndrome ≤ 3.0×ULN).\n8. The subject and their spouse agree to take effective contraceptive measures (excluding safe period contraception) from the time of signing the informed consent form by the subject until one year after IASO207 injection treatment.\n9. The subject must agree to sign or personally write and present the signed informed consent form approved by the ethics committee before starting any screening procedure.\n\nExclusion Criteria:\n\nDisease-related:\n\n1. Diagnosed with drug-induced SLE.\n2. Complicated with other autoimmune diseases that may affect the assessment of the study, including but not limited to Sjögren's syndrome, psoriasis, rheumatoid arthritis.\n3. Had a catastrophic antiphospholipid syndrome or developed a severe antiphospholipid syndrome within 1 year before screening.\n4. The study disease involved neurological symptoms with a BILAG-2004 activity score of class A.\n\n   Other medical history-related:\n5. Known primary immunodeficiency (congenital or acquired).\n6. The subject has uncontrollable active fungal, viral, bacterial or other infections (existing persistent infection-related signs\u002Fsymptoms, not improved after appropriate anti-infection treatment) or requires intravenous anti-infection drug treatment for infection.\n7. Positive hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb) and abnormal peripheral blood hepatitis B virus (HBV) DNA detection (defined as HBV DNA quantification above the normal reference range of the testing center or positive HBV DNA qualitative detection); positive hepatitis C virus (HCV) antibody and positive peripheral blood hepatitis C virus (HCV) RNA; positive Human Immunodeficiency Virus (HIV) antibody; positive cytomegalovirus (CMV) DNA detection; positive Treponema pallidum specific antibody and positive rapid plasma reagin test for syphilis.\n8. Severe heart disease: including but not limited to unstable angina pectoris and\u002For myocardial infarction within 12 months of screening, any congestive heart failure (NYHA classification ≥ III), and a history of severe arrhythmia; or left ventricular ejection fraction (LVEF) \\\u003C 45%.\n9. Severe asthma or chronic obstructive pulmonary disease (COPD), with stable treatment considered for mild or moderate asthma or COPD by the investigator and sponsor; or resting arterial blood oxygen saturation \\\u003C 91%.\n10. Evaluated by the investigator as having a severe bleeding risk.\n11. Evaluated by the investigator as having severe liver dysfunction.\n12. History of severe kidney disease; or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.\n13. Acute cerebrovascular disease events occurred within 6 months before enrollment, including transient ischemic attack or stroke history.\n14. Any severe and\u002For uncontrolled comorbid diseases as assessed by the investigator.\n15. Had a malignant tumor within 5 years before screening, excluding cured cervical carcinoma in situ, basal cell or squamous cell skin cancer, locally advanced prostate cancer after radical surgery, breast duct carcinoma in situ after radical surgery, or papillary thyroid carcinoma after radical surgery.\n16. Had a clear history of mental disorder or a history of substance abuse for mental disorders that cannot be quit.\n17. Known allergy to the components of IASO207 injection or to the supportive drugs required for the toxicity management of CAR-T cell therapy (such as tocilizumab).\n\n    Previous and concurrent treatments:\n18. History of organ transplantation.\n19. History of autologous or allogeneic stem cell transplantation.\n20. History of cell therapy or CD19-targeted drug treatment.\n21. Received targeted CD20 biologic therapy within 12 weeks before screening, such as rituximab, obinutuzumab.\n22. Received plasma exchange or immunoadsorption treatment within 12 weeks before screening.\n23. Had or planned to have major surgery or surgical treatment caused by any reason within 12 weeks before screening.\n24. Have participated in the treatment of other investigational drugs (except for placebo) within the previous 4 weeks or 5 half-lives (whichever is longer);\n25. Have received a BAFF antagonist, such as belimumab or tixagevimab, within the previous 4 weeks;\n26. Have received live attenuated vaccine within the previous 4 weeks;\n27. Pregnant or lactating women;\n28. Other situations deemed unsuitable for inclusion by the investigators.",{"count":231,"type":22},[233],"This is a single-center, open-label, exploratory clinical study designed to evaluate the efficacy and safety of IASO207 Injection (in vivo CAR-T) in patients with active refractory systemic lupus erythematosus.",[535],"REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS",[537,239,538],"systemic lupus erythematosus","in vivo CAR-T",{"date":220,"type":37},{"date":449,"type":22},{"date":542,"type":22},"2030-05-30",{"name":43,"class":44},{"id":545,"slug":4,"hasResults":11,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":45},"100640823","NCT07588594","Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia","Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia","Inclusion Criteria:\n\n* Age ≥ 18 years, any sex\u002Fgender.\n* Confirmed diagnosis of chronic myelomonocytic leukemia (CMML) according to the 2022 WHO classification.\n* Intermediate-2 or high-risk CMML based on CPSS or CPSS-mol score, and planned to receive allo-HSCT.\n* Has a suitable hematopoietic stem cell donor:\n* For haploidentical donor: at least 5\u002F10 HLA match at HLA-A, -B, -C, -DQB1, and -DRB1.\n* For unrelated donor: at least 9\u002F10 HLA match at the same five loci.\n* For matched sibling donor: 10\u002F10 HLA match at the same five loci.\n* Hematopoietic cell transplantation comorbidity index (HCT-CI) ≤ 2, with generally good health and no significant organ abnormalities or major comorbidities.\n* Adequate organ function as defined below:\n* Left ventricular ejection fraction (LVEF) ≥ 50%, and no uncontrolled tachycardia or bradycardia-tachycardia syndrome.\n* Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT ≤ 2 × ULN; AST ≤ 2 × ULN.\n* Serum creatinine ≤ 1.5 × ULN.\n* Baseline oxygen saturation \\> 92%.\n* Pulmonary function: DLCO (corrected for hemoglobin) ≥ 40%, FEV1 ≥ 50%.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Agrees not to participate in any other interventional study during the treatment period.\n* Willing and able to provide written informed consent, understand the nature, purpose, and procedures of the study, and voluntarily comply with study requirements.\n\nExclusion Criteria:\n\n* Previous allogeneic HSCT for CMML that later relapsed.\n* Unwilling or unable to receive the study treatment regimen.\n* Active hepatitis B or C, or chronic active hepatitis; known human immunodeficiency virus (HIV) infection.\n* Active uncontrolled infection, including: hemodynamic instability related to infection, new or worsening signs\u002Fsymptoms of infection, new infection lesions on imaging, or persistent fever without explanation despite no symptoms\u002Fsigns.\n* History of stroke or intracranial hemorrhage within 6 months before enrollment.\n* Known pregnancy (positive urine pregnancy test), or currently breastfeeding.\n* Diagnosis of another malignancy within the past 2 years, except for localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, breast cancer, or localized prostate cancer (Gleason score ≤ 6) that has been treated with curative intent.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.",{"count":551,"type":22},31,[57],"This is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with chronic myelomonocytic leukemia (CMML) who have an intermediate-2 or high-risk prognosis.\n\nThe main goal is to evaluate 1 year RFS and OS. Other goals include assessing engraftment, overall survival, transplant-related complications, and side effects. A total of 31 participants will be enrolled.",[555],"Chronic Myelomonocytic Leukemia (CMML)",[555,557,558],"Hematopoietic Stem Cell Transplantation (HSCT)","Thiotepa","2026-05-21",{"date":561,"type":37},"2026-05-26",{"date":563,"type":37},"2026-02-13",{"date":565,"type":22},"2028-05",{"name":43,"class":44},{"id":568,"slug":4,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":81,"conditions":571,"keywords":572,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":577,"leadSponsor":578,"locationsCount":4},"100639594",{"count":78,"type":22},[80],[83,84],[86,87,88,89],"2026-05-14",{"date":575,"type":37},"2026-05-20",{"date":220,"type":22},{"date":94,"type":22},{"name":43,"class":44},{"id":580,"slug":4,"hasResults":11,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":45},"100640893","NCT07597395","ATRA for Management of Primary ITP","All-trans Retinoic Acid for Management of Primary Immune Thrombocytopenia : a Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n* Primary ITP if aged ⩾18 years;\n* With an average of two platelet counts ⩾1 day apart of \\\u003C30×10\\^9\u002FL during screening and no single platelet count \\>35×10\\^9\u002FL within 2 weeks before study treatment;\n* Patients who have previously received at least one first-line standard therapy for ITP (corticosteroid and\u002For intravenous immunoglobulin) with unsustained efficacy, relapse, intolerance to standard therapy, or insufficient response.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant;\n* With active malignancy or a history of malignant tumor;\n* Having experienced severe bacterial, viral, fungal or parasitic infection within the past 4 weeks;\n* With a history of symptomatic herpes zoster infection within 12 weeks prior to screening;\n* Active or chronic HBV, HCV or HIV infection;\n* Evidence of active tuberculosis; or previous evidence of active tuberculosis without appropriate and documented treatment; or household contact with patients with active tuberculosis without appropriate and documented tuberculosis prophylaxis;\n* Receipt of live vaccines within the past 12 weeks, or planned live vaccination during the study period;\n* Prior ATRA therapy;\n* History of solid organ transplant or planned surgery;\n* Myelodysplastic syndrome, aplastic anemia or myelofibrosis;\n* Patients with other diseases were undergoing treatment with immunosuppressants;\n* Clinically significant thromboembolic events within the past 24 weeks, or ongoing anticoagulant treatment, who are deemed ineligible for the study by the investigator;\n* History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure;\n* History or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, neurological, neuropsychiatric or any other severe and\u002For unstable diseases that, in the opinion of the investigator, may pose an unacceptable risk with the investigational product or interfere with the interpretation of study data;\n* AST \\> 2 times the upper limit of normal (ULN), ALT \\> 2×ULN, TBIL ≥ 1.5×ULN;\n* WBC \\\u003C 2500\u002FµL, neutrophil count \\\u003C 1200\u002FµL, lymphocyte count \\\u003C 750\u002FµL, hemoglobin \\\u003C 9 g\u002FdL;\n* eGFR \\\u003C 50 mL\u002Fmin\u002F1.73m²;\n* Other patients deemed unsuitable for enrollment in this study by the investigator.",{"count":586,"type":22},192,[588],"PHASE3","A multicenter, randomized, double-blind placebo-controlled study to report the efficacy and safety of all-trans etinoic acid compared to placebo for the treatment of adults with corticosteriod-resistant\u002Frelapsed primary immune thrombocytopenia (ITP).",[591],"Immune Thrombocytopenia",[593,594,595],"Immune thrombocytopenia;","Corticosteriod resistance resistant\u002Frelaped","ATRA","2026-05-13",{"date":598,"type":37},"2026-05-19",{"date":600,"type":22},"2026-05-30",{"date":222,"type":22},{"name":43,"class":44},""]